247 related articles for article (PubMed ID: 21533812)
1. Differential expression of cytokines in breast cancer patients receiving different chemotherapies: implications for cognitive impairment research.
Janelsins MC; Mustian KM; Palesh OG; Mohile SG; Peppone LJ; Sprod LK; Heckler CE; Roscoe JA; Katz AW; Williams JP; Morrow GR
Support Care Cancer; 2012 Apr; 20(4):831-9. PubMed ID: 21533812
[TBL] [Abstract][Full Text] [Related]
2. Cognitive impairment and elevated peripheral cytokines in breast cancer patients receiving chemotherapy.
Khan MA; Bhurani D; Hoda U; Sehar N; Agarwal N
Arq Neuropsiquiatr; 2022 Aug; 80(8):786-793. PubMed ID: 36252586
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group. Danish Breast Cancer Cooperative Group (DBCG).
Andersson M; Madsen EL; Overgaard M; Rose C; Dombernowsky P; Mouridsen HT
Eur J Cancer; 1999 Jan; 35(1):39-46. PubMed ID: 10211086
[TBL] [Abstract][Full Text] [Related]
4. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.
Hutchins LF; Green SJ; Ravdin PM; Lew D; Martino S; Abeloff M; Lyss AP; Allred C; Rivkin SE; Osborne CK
J Clin Oncol; 2005 Nov; 23(33):8313-21. PubMed ID: 16293862
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life in axillary node-negative, estrogen receptor-negative breast cancer patients undergoing AC versus CMF chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project B-23.
Land SR; Kopec JA; Yothers G; Anderson S; Day R; Tang G; Ganz PA; Fisher B; Wolmark N
Breast Cancer Res Treat; 2004 Jul; 86(2):153-64. PubMed ID: 15319567
[TBL] [Abstract][Full Text] [Related]
6. Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients.
Schagen SB; Muller MJ; Boogerd W; Rosenbrand RM; van Rhijn D; Rodenhuis S; van Dam FS
Ann Oncol; 2002 Sep; 13(9):1387-97. PubMed ID: 12196364
[TBL] [Abstract][Full Text] [Related]
7. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15.
Paik S; Bryant J; Tan-Chiu E; Yothers G; Park C; Wickerham DL; Wolmark N
J Natl Cancer Inst; 2000 Dec; 92(24):1991-8. PubMed ID: 11121461
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group.
Martin M; Villar A; Sole-Calvo A; Gonzalez R; Massuti B; Lizon J; Camps C; Carrato A; Casado A; Candel MT; Albanell J; Aranda J; Munarriz B; Campbell J; Diaz-Rubio E;
Ann Oncol; 2003 Jun; 14(6):833-42. PubMed ID: 12796019
[TBL] [Abstract][Full Text] [Related]
9. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC
J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326
[TBL] [Abstract][Full Text] [Related]
10. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma.
Schagen SB; van Dam FS; Muller MJ; Boogerd W; Lindeboom J; Bruning PF
Cancer; 1999 Feb; 85(3):640-50. PubMed ID: 10091737
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B.
Aisner J; Weinberg V; Perloff M; Weiss R; Perry M; Korzun A; Ginsberg S; Holland JF
J Clin Oncol; 1987 Oct; 5(10):1523-33. PubMed ID: 3655855
[TBL] [Abstract][Full Text] [Related]
12. Surgical adjuvant chemotherapy for breast cancer: a comparison of CMF and CAF regimens.
Babar AM
J Pak Med Assoc; 1991 Dec; 41(12):293-6. PubMed ID: 1824559
[TBL] [Abstract][Full Text] [Related]
13. Relationship of systemic cytokine concentrations to cognitive function over two years in women with early stage breast cancer.
Lyon DE; Cohen R; Chen H; Kelly DL; McCain NL; Starkweather A; Ahn H; Sturgill J; Jackson-Cook CK
J Neuroimmunol; 2016 Dec; 301():74-82. PubMed ID: 27890459
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
Bang SM; Heo DS; Lee KH; Byun JH; Chang HM; Noh DY; Choe KJ; Bang YJ; Kim SR; Kim NK
Cancer; 2000 Dec; 89(12):2521-6. PubMed ID: 11135211
[TBL] [Abstract][Full Text] [Related]
15. Long-term survival of patients treated with combination chemotherapy for metastatic breast cancer.
Falkson G; Tormey DC; Carey P; Witte R; Falkson HC
Eur J Cancer; 1991; 27(8):973-7. PubMed ID: 1832906
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) or cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in 69 cases of locally advanced (stage IIIb) breast cancer.
Gupta P; Bijlani L; Rath GK; Misra A; Mishra MC; Shukla NK; Kriplani A; Kapur BM
Jpn J Surg; 1991 Nov; 21(6):637-42. PubMed ID: 1787609
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy in early breast cancer.
Ejlertsen B
Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
[TBL] [Abstract][Full Text] [Related]
18. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.
Fisher B; Brown AM; Dimitrov NV; Poisson R; Redmond C; Margolese RG; Bowman D; Wolmark N; Wickerham DL; Kardinal CG
J Clin Oncol; 1990 Sep; 8(9):1483-96. PubMed ID: 2202791
[TBL] [Abstract][Full Text] [Related]
19. Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort study.
Cheung YT; Ng T; Shwe M; Ho HK; Foo KM; Cham MT; Lee JA; Fan G; Tan YP; Yong WS; Madhukumar P; Loo SK; Ang SF; Wong M; Chay WY; Ooi WS; Dent RA; Yap YS; Ng R; Chan A
Ann Oncol; 2015 Jul; 26(7):1446-51. PubMed ID: 25922060
[TBL] [Abstract][Full Text] [Related]
20. Course of mental fatigue and motivation in breast cancer patients receiving adjuvant chemotherapy.
de Jong N; Candel MJ; Schouten HC; Abu-Saad HH; Courtens AM
Ann Oncol; 2005 Mar; 16(3):372-82. PubMed ID: 15677622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
